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EP-1027  
Re treatment in previously irradiated neck. The different 
problems of relapsed and second cancers 
C. Krzisch
1CHU Amiens - Hôpital Sud, Radiation Oncology, Salouel, 
France 
1, E. Ecker1, S. Gabriel1, A.R. Henry1, A. Coutte1 
 
Purpose or Objective: Owing to legitimate fears concerning 
potentially devastating complications, the treatment of head 
and neck cancer in previously irradiated patient has been 
based on surgery for the best cases and chemotherapy for the 
inoperable ones. We review our series of 84 routinely re-
(chemot)irradiated patients since 2000. 
 
Material and Methods: Patients : 84 consecutive patients, 
mean age 60.47, previously treated by radio(chemo)therapy 
with a median delay between the the two irradiations of 36.3 
months have been treated. 54 patients with relapses and 30 
patients presenting second cancers . The mean follow-up is 
66.45 months.  
Methods : 42 patients were operated upon, 
(chemo)radiotherapy being used postoperatively for poor 
prognostic factors. 42 inoperable patients have been treated 
exclusively by radiochemotherapy. Before 2007, patients 
were treated by 2D techniques then by IMRT. 44 received 
concomitant platinum-based chemotherapy, 23 cetuximab 
and 17 radiotherapy alone. 
 
Results: Results : median overall survival for the entire 
population is 19.61 months. Specific survival 23 
months.Death causes : 40 the cancer itself, 9 patients 
complications et 11 other causes. Prognostic factors : age, 
sexe, performance status, Charlson score, location, type of 
resurgence (local, nodal or both), surgery, chemotherapy 
antecedents, type of concomitant treatment during the 
reirradiation, previous disabilities (tracheostomy, nasogastric 
tube) have been investigated. Only the type of resurgence is 
discriminant with a median survival time of 16.49 months for 
patients treated for a relapse and 32 months for those 
treated for a second cancer (Logrank p=0.00464). 
Complications : 9 deceased : 1 carotid blowout (with 
evolutive tumor), 3 late pneumoniae (patient NED), 3 
tumoral hemorrhages (evolutive tumors) and 2 unknown 
complications. Late sequellae: 10 radionecrosis (7 
osteoradionecrosis), 7 persistant dysphagia, 8 long term 
fistulas. 
 
Conclusion: Conclusion :The survival in our series restricted 
to the second cancers is similar to that obtained in not 
previously irradiated patients and confirm some data of the 
literature. Thereby it is our belief that, if the acceptance of 
this strategy of treatment may merit further clinical trials for 
the relapsing tumor (however the results compare favorably 
with palliative chemotherapy), it becomes unethical not to 
give this chance for the second cancers in spite of the risk of 
severe complication. 
 
EP-1028  
The role of adjuvant external beam radiation therapy for 
advanced papillary thyroid cancer 
C.Y. Kim
1Korea University Anam Hospital, Radiation Oncology, Seoul, 
Korea Republic of 
1, N.K. Lee1, K.Y. Jung2, S.K. Baek2 
2Korea University Anam Hospital, Otolaryngology–Head and 
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Purpose or Objective: the purpose of this study was to 
investigate the prognostic implication of adjuvant external 
beam radiation therapy on the locoregional control in 
patients with either locally advanced thyroid papillary 
carcinoma or cervical lymph node involvement. 
 
Material and Methods: retrospective analysis was performed 
on 165 patients with locally advanced thyroid papillary 
carcinoma (T4) or cervical lymph node involvement (N1b), 
who were treated between 2002 and 2011. Of these, 32 
patients were treated with total thyroidectomy followed by 
adjuvant external beam radiation therapy and radioactive 
iodine treatment, and 133 patients were treated with total 
thyroidectomy followed by radioactive iodine treatment. 
 
Results: The median follow-up time was 223 months (range, 
93 to 421 months). The 10-year disease-free survival and 
locoregional relapse-free survival rates were significantly 
better than unirradiated controls. 10-year disease-free 
survival rates for patients in the radiation therapy and no 
radiation therapy groups were 84.3% and 56.7%, respectively 
(p = 0.049). 10-year locoregional relapse-free survival rates 
for patients in the radiation therapy and no radiation therapy 
groups were 83.9% and 60.8%, respectively (p = 0.037). The 
overall survival rate and distant relapse-free survival rate 
were not different between the two groups. Multivariate 
analysis showed that adjuvant radiation therapy was an 
independent prognostic factor for locoregional relapse-free 
survival (p = 0.044). 
 
Conclusion: adjuvant external beam radiation therapy should 
be considered in patients with either pT4 disease or cervical 
lymph node involvement. 
 
EP-1029  
20 v. 25-35 fractions in Oropharyngeal Carcinoma 
chemoIMRT: Could fraction number be de-escalated? 
B. Cheng
1InHANSE, Radiotherapy Quality Assurance, Birmingham, 
United Kingdom 
1, H. Benghiat2, J. Glaholm2, H. Mehanna1, P. 
Sanghera1, A. Hartley1 
2Hall-Edwards Radiotherapy Research Group, Queen 
Elizabeth Hospital, Birmingham, United Kingdom 
 
Purpose or Objective: Highly conformal dose distributions 
produced by rotational IMRT reliably delivered with daily 
IGRT raise the possibility that radical chemoIMRT for 
oropharyngeal carcinoma could be delivered in fewer 
fractions (#) for certain subgroups. The purpose of this study 
was to compare two cohorts of patients with oropharyngeal 
carcinoma treated within a single centre: the first treated 
with a 20# (4 weeks(wk)) schedule, the second with 25-35# 
(5-7wk) schedules. 
 
Material and Methods: Patients undergoing radical 
chemoIMRT between June 2009 and May 2012 were treated 
with 55Gy/20# over 25 days to PTV1 with synchronous 
carboplatin or cetuximab (20# cohort). Similar patients were 
treated between June 2012 and April 2014 with one of three 
schedules 64Gy/25# over 32 days, 65Gy/30# over 39 days or 
70Gy/35# over 46 days to PTV 1 with synchronous cisplatin or 
cetuximab (25-35# cohort). The local control (LC) and overall 
survival (OS) of these two cohorts were compared using the 
log-rank test. 
 
Results: The minimum time elapsed from treatment in all 
patients was 18 months. There were 86 patients in the 20# 
cohort: median age 58 years; p16+ 60 (70%); T4 28 (33%); 
N2C/N3 16 (19%). There were 77 patients in the 25-35# 
cohort: median age 59 years; p16+ 54 (70%); T4 24 (32%); 
N2C/N3 16 (22%). The 18 month local control in the two 
cohorts respectively was 86% v. 88% (p=0.69). The 18 month 
overall survival was 85% v. 89% (p=0.41). If the two cohorts 
were restricted to those patients who were p 16+ve, T1-3, no 
neo-adjuvant chemotherapy and platinum agent used 
synchronously the corresponding figures (n= 26 for 20# cohort 
v. n=38 for 25-35# cohort) for local control were 92% v. 95% 
(p=0.34) and for overall survival 96% v 100% (p=0.22). 
 
Conclusion: Although further follow up and late toxicity data 
is required, the similarity in results seen between the two 
cohorts in this study warrant the testing of the 20# schedule 
with synchronous cisplatin in a randomised setting in good 
prognosis oropharyngeal patients. This similarity in the 
endpoints studied is evidence against synchronous 
chemotherapy acting to reduce accelerated repopulation 
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during chemoradiation and further models to account for the 
effect of synchronous chemotherapy should be investigated.  
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Sentinel lymph node biopsy in clinically N0 laryngeal 
cancer: validation and application 
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Purpose or Objective: Cervical lymph node dissection for 
laryngeal cancer patients without clinical and radiologic 
evidence of regional metastasis (N0) is controversial. Aim of 
our study was to validate sentinel lymph node biopsy (SLNB) 
procedure and evaluate its applicability in early T1-2 N0 
laryngeal SCC. 
 
Material and Methods: A prospective study conducted at the 
Lithuanian University of Health Sciences Hospital, with the 
permission of institutional review board. Inclusion period 
2010 – 2013y. Patients with histologically confirmed laryngeal 
SCC T1-2, N0 were involved. Two phase design: validation 
phase - SLNB and selective neck dissection (SND) were 
performed simultaneously; application phase - SND was 
performed according to SLNB outcome. The end points for 
SLNB validation phase: sensitivity, specificity, negative-
predictive value (NPV). Patients from both phases were 
followed-up after treatment and compared for recurrence-
free survival (RFS). Sentinel lymph nodes (SLN) were located 
by 99mTc lymphoscintigraphy and gamma probe. Pathological 
evaluation included hematoxylin and eosin staining and 
immunohistochemistry. Statistical analysis was performed by 
using SPSS® v20.0, Clinical Calculator 1, ©Richard Lowry 
2001-2015.The Pearson X2 was used for categorical data. 
Significant p-value <0.05. RFS was investigated performing a 
log-rank test. 
 
Results: Clinicopathological features presented in table 1. In 
SLNB validation period we involved 16 pts. The mean number 
of SLNs per patient was 2.3. Four patients had positive SLN, 
no false positive results found. 12 pts had negative SLN, one 
of them had positive SND histological findings. The 
prevalence of positive lymph nodes was 0.31 (95% CI 0.12-
0.58), overall sensitivity was 0.8 (95% CI 0.29-0.98), 
specificity was 1 (95% CI 0.67-1). NPV of SLNB equal to 0.91 
(95% CI 0.59-0.99). During whole study period 46 pts were 
involved. The median of SLN removed per patient was 2.2. 
The total neck control rate was 87% and did not differ 
between validation and application groups (p=0.4). In a mean 
follow up period of 24 months, mean RFS time for validation 
group was 42 months (95%CI 37.36-48.28) vs 40 months in 
application group (95%CI 32.02-48.13), with no significant 
difference (p=0.43). 
 
Conclusion: More comprehensive study with a larger group of 
patients and longer follow-up is needed in order to confirm 
SLNB applicability, however preliminary data revealed SLNB 
as sensitive and specific with no negative influence on 
recurrence-free survival.  
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Does oral mucosa OAR dose predict duration of G3 
mucositis following IMRT for oropharynx cancer? 
S. Yahya
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1, H. Benghiat1, P. Nightingale1, M. Tiffany1, P. 
Sanghera2, A. Hartley2 
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Kingdom 
 
Purpose or Objective: Various methods have been described 
to delineate the oral mucosa organ at risk (OAR). Due to 
uncertainty in the literature, the purpose of this study was to 
examine whether dose delivered to two versions of this OAR 
correlated to the duration of acute grade 3 mucositis in 
patients with oropharyngeal carcinoma treated with intensity 
modulated radiotherapy (IMRT). 
 
Material and Methods: 66 patients previously treated with 
IMRT (55GY in 20 fractions over 25 days to the high dose 
volume; 46 in 20 fractions to areas at risk of harbouring 
microscopic disease) and synchronous carboplatin or 
cetuximab were included in this study. The duration of 
CTCAE version (v) 3 grade 3 mucositis (G3M) and the duration 
of strong opiate use (a surrogate for CTCAE v4 G3M) had been 
prospectively recorded at the time of treatment. Standard 
and modified oral mucosa OARs were contoured and the 
following dose parameters derived: mean dose, V55, V50, 
V45, V40 and V30. 
Spearman’s correlation was used to investigate for a 
relationship between the duration of v3 G3M or strong opiate 
use and these dose parameters for each OAR and 6 additional 
patient factors: pre-radiotherapy haemoglobin, weight, age, 
smoking status, use of neo-adjuvant chemotherapy and 
synchronous chemotherapy (carboplatin v. cetuximab). 
 
Results: No statistically significant correlation of v3 G3M or 
duration of strong opiate use was noted with the tested 
parameters with the exception of a trend towards 
significance with pre-treatment weight (p=0.053). Duration 
of opiate use was found be to be approximately proportional 
to pre-treatment weight. 
 
Conclusion: This study failed to show a relationship between 
dose to the standard or modified oral mucosa OAR and the 
duration of CTCAE v3 G3M or duration of opiate use in 
patients undergoing IMRT for oropharyngeal cancer. Further 
work is required to test these models with particle therapy 
where lower dose distributions to oral mucosa may be 
achievable. The utility of CTCAE v4 G3M as an endpoint if 
confirmed in larger studies to be related to pre-treatment 
weight is questioned by this study. 
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Unilateral neck radiotherapy in HPV-related tonsillar 
carcinomas 
K. Thippu Jayaprakash
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Purpose or Objective: Unilateral neck radiotherapy is 
considered a standard treatment for well-lateralized 
squamous cell carcinomas of the tonsil related to a HPV 
infection. Well-lateralized tumours are defined as T0-T2 N0-
N2b M0 and not invading the base of tongue nor extending 
more than 1 cm into the soft palate. We performed a 
retrospective review aiming to assess the risk of a 
contralateral neck recurrence in this group of patients with a 
particular focus on those diagnosed with N2b disease. 
 
Material and Methods: Fifty patients with T0-T3 N0-2b M0 
disease (only two had T3 tumours) were treated with 
unilateral 3DCRT between February 2004 and July 2011. All 
50 patients had p16-positive tumours. They all received 
chemotherapy (concomitant, induction or both) apart from 
two. Twenty-six patients presented with N2b disease. Median 
follow-up was 54 months. 
 
Results: Four patients relapsed in the contralateral neck with 
no evidence of local or ipsilateral regional failure; one with 
recurrent contralateral retropharyngeal nodes and the rest 
with contralateral level II-IV nodes. Median time to a 
contralateral recurrence was 32 months (range, 22-47 
months). All 4 patients initially presented with T1 N2b M0 
disease. Upon recurrence, 2 of these patients were treated 
with a salvage neck dissection followed by chemoradiation 
and 2 with re-irradiation. Both re-irradiation patients 
developed a further recurrence and one of them died of his 
